{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:22:33Z","timestamp":1792027353715,"version":"4.4.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001704","name":"European Society of Clinical Microbiology and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000805","name":"European Centre for Disease Prevention and Control","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000805","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.cmi.2020.04.027","type":"journal-article","created":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T16:56:36Z","timestamp":1588006596000},"page":"1039-1043","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":74,"title":["Daptomycin in the treatment of enterococcal bloodstream infections and endocarditis: a EUCAST position paper"],"prefix":"10.1016","volume":"26","author":[{"given":"J.","family":"Turnidge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Kahlmeter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Cant\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"MacGowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.G.","family":"Giske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2020.04.027_bib1","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1093\/jac\/dky072","article-title":"Association of daptomycin dosing regimen and mortality in patients with VRE bacteraemia: a review","volume":"73","author":"Foolad","year":"2018","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2020.04.027_bib2","first-page":"1","article-title":"Comparison of linezolid and daptomycin for the treatment of vancomycin-resistant enterococcal bacteremia","volume":"6","author":"Narayanan","year":"2019","journal-title":"Ther Adv Infect Dis"},{"key":"10.1016\/j.cmi.2020.04.027_bib3","unstructured":"European Medicines Agency. Cubicin \u2013 Summary of product characteristics. Date of latest renewal: 29 November 2010. Accessed 12 December 12 2019. https:\/\/www.ema.europa.eu\/documents\/product-information\/cubicin-epar-product-information_en.pdf"},{"key":"10.1016\/j.cmi.2020.04.027_bib4","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/j.1469-0691.2006.01455.x","article-title":"EUCAST technical note on daptomycin","volume":"12","author":"European Committee on Antimicrobial Susceptibility Testing Steering","year":"2006","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2020.04.027_bib5","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11908-017-0589-2","article-title":"Treatment of vancomycin-resistant enterococci: focus on daptomycin","volume":"19","author":"Kohinke","year":"2017","journal-title":"Curr Infect Dis Rep"},{"key":"10.1016\/j.cmi.2020.04.027_bib6","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1128\/AAC.48.1.63-68.2004","article-title":"In\u00a0vivo pharmacodynamic activity of daptomycin","volume":"48","author":"Safdar","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2020.04.027_bib7","doi-asserted-by":"crossref","first-page":"e00506","DOI":"10.1128\/AAC.00506-18","article-title":"Pharmacodynamics of daptomycin against Enterococcus faecium and Enterococcus faecalis in the murine thigh infection model","volume":"62","author":"Kidd","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2020.04.027_bib8","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1093\/cid\/ciy749","article-title":"Pharmacodynamic analysis of daptomycin-treated enterococcal bacteremia: it is time to change the breakpoint","volume":"68","author":"Avery","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2020.04.027_bib9","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1093\/jac\/dkr551","article-title":"Multiple-dose pharmacokinetics of daptomycin during continuous venovenous haemodiafiltration","volume":"67","author":"Wenisch","year":"2012","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"4","key":"10.1016\/j.cmi.2020.04.027_bib10","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3390\/antibiotics8040245","article-title":"Optimizing the Dosing regimens of daptomycin based on the susceptible dose-dependent breakpoint against vancomycin-resistant enterococci infection","volume":"8","author":"Santimaleeworagun","year":"2019","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.cmi.2020.04.027_bib11","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s42770-019-00200-4","article-title":"Time-kill curves of daptomycin and Monte Carlo simulation for the treatment of bacteraemia caused by Enterococcus faecium","volume":"51","author":"Menezes","year":"2020","journal-title":"Braz J Microbiol"},{"issue":"6","key":"10.1016\/j.cmi.2020.04.027_bib12","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/jcph.1576","article-title":"Pharmacokinetic\/pharmacodynamic analysis of daptomycin against Staphylococcus aureus and Enterococcus faecium in pediatric Patients by Monte Carlo simulation","volume":"60","author":"Wei","year":"2020","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.cmi.2020.04.027_bib13","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.cmi.2016.07.018","article-title":"Daptomycin versus linezolid for the treatment of vancomycin-resistant enterococcal bacteraemia: implications of daptomycin dose","volume":"22","author":"Chuang","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2020.04.027_bib14","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1093\/cid\/ciw815","article-title":"Comparative effectiveness and safety of standard-, medium-, and high-dose daptomycin strategies for the treatment of vancomycin-resistant enterococcal bacteremia among veterans affairs patients","volume":"64","author":"Britt","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2020.04.027_bib15","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1093\/cid\/cix024","article-title":"Effect of daptomycin dose on the outcome of vancomycin-resistant, daptomycin-susceptible Enterococcus faecium bacteremia","volume":"64","author":"Chuang","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2020.04.027_bib16","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1093\/cid\/ciw173","article-title":"Influence of minimum inhibitory concentration in clinical outcomes of Enterococcus faecium bacteremia treated with daptomycin: is it time to change the breakpoint?","volume":"62","author":"Shukla","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2020.04.027_bib17","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1093\/jac\/dkr255","article-title":"Vancomycin-resistant enterococcal bacteraemia and daptomycin: are higher doses necessary?","volume":"66","author":"King","year":"2011","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2020.04.027_bib18","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1097\/CCM.0000000000003264","article-title":"Survival of patients with vancomycin-resistant Enterococcus faecium bacteremia treated with conventional or high doses of daptomycin or linezolid is associated with the rate of bacterial Clearance","volume":"46","author":"Chuang","year":"2018","journal-title":"Crit Care Med"},{"key":"10.1016\/j.cmi.2020.04.027_bib19","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1128\/AAC.00526-13","article-title":"Multicenter study of high-dose daptomycin for treatment of enterococcal infections","volume":"57","author":"Casapao","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2020.04.027_bib20","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1016\/j.clinthera.2016.09.011","article-title":"Vancomycin-resistant enterococcal bloodstream infections in hematopoietic stem cell transplant recipients and patients with hematologic malignancies: impact of daptomycin MICs of 3 to 4 mg\/L","volume":"38","author":"Chong","year":"2016","journal-title":"Clin Ther"},{"key":"10.1016\/j.cmi.2020.04.027_bib21","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1093\/jac\/dkq087","article-title":"A\u00a0potential role for daptomycin in enterococcal infections: what is the evidence?","volume":"65","author":"Canton","year":"2010","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2020.04.027_bib22","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1093\/jac\/dku004","article-title":"Efficacy of daptomycin in the treatment of enterococcal endocarditis: a 5 year comparison with conventional therapy","volume":"69","author":"Ceron","year":"2014","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2020.04.027_bib23","doi-asserted-by":"crossref","first-page":"6213","DOI":"10.1128\/AAC.01563-13","article-title":"High-dose daptomycin therapy for left-sided infective endocarditis: a prospective study from the international collaboration on endocarditis","volume":"57","author":"Carugati","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2020.04.027_bib24","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1093\/jac\/dkt294","article-title":"A\u00a0multicentre evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of infective endocarditis","volume":"68","author":"Kullar","year":"2013","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2020.04.027_bib25","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s40121-019-00261-w","article-title":"Should high-dose daptomycin be an alternative treatment regimen for enterococcal endocarditis?","volume":"8","author":"Peghin","year":"2019","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.cmi.2020.04.027_bib26","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1161\/CIR.0000000000000296","article-title":"Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association","volume":"132","author":"Baddour","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.cmi.2020.04.027_bib27","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1093\/eurheartj\/ehv319","volume":"36","author":"Habib","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cmi.2020.04.027_bib28","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1086\/652767","article-title":"Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis","volume":"50","author":"Bhavnani","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2020.04.027_bib29","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1007\/s12325-015-0267-4","article-title":"Evaluation of effectiveness and safety of high-dose daptomycin: results from patients included in the European Cubicin((R)) outcomes registry and experience","volume":"32","author":"Seaton","year":"2015","journal-title":"Adv Ther"},{"issue":"9","key":"10.1016\/j.cmi.2020.04.027_bib30","doi-asserted-by":"crossref","first-page":"e00745","DOI":"10.1128\/AAC.00745-18","article-title":"Variability of daptomycin MIC values for Enterococcus faecium when measured by reference broth microdilution and gradient diffusion tests","volume":"62","author":"Campeau","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2020.04.027_bib31","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/mmi.14193","article-title":"LiaR-independent pathways to daptomycin resistance in Enterococcus faecalis reveal a multilayer defense against cell envelope antibiotics","volume":"111","author":"Miller","year":"2019","journal-title":"Mol Microbiol"},{"key":"10.1016\/j.cmi.2020.04.027_bib32","doi-asserted-by":"crossref","first-page":"5253","DOI":"10.1128\/AAC.00098-14","article-title":"Defining daptomycin resistance prevention exposures in vancomycin-resistant Enterococcus faecium and E. faecalis","volume":"58","author":"Werth","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.cmi.2020.04.027_bib33","article-title":"Influence of inoculum effect on the efficacy of daptomycin monotherapy and in combination with beta-lactams against daptomycin-susceptible Enterococcus faecium harboring LiaSR substitutions","volume":"63","author":"Kebriaei","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2020.04.027_bib34","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.ijantimicag.2016.07.006","article-title":"Mutant prevention concentrations of daptomycin for Enterococcus faecium clinical isolates","volume":"48","author":"Sinel","year":"2016","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"10.1016\/j.cmi.2020.04.027_bib35","doi-asserted-by":"crossref","first-page":"e01800","DOI":"10.1128\/AAC.01800-18","article-title":"Impact of an antimicrobial stewardship intervention on within- and between-patient daptomycin resistance evolution in vancomycin-resistant Enterococcus faecium","volume":"63","author":"Kinnear","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2020.04.027_bib36","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1128\/JCM.00957-14","article-title":"Comparison of commercial antimicrobial susceptibility test methods for testing of Staphylococcus aureus and Enterococci against vancomycin, daptomycin, and linezolid","volume":"52","author":"Riedel","year":"2014","journal-title":"J\u00a0Clin Microbiol"},{"issue":"6","key":"10.1016\/j.cmi.2020.04.027_bib37","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1093\/cid\/ciz845","article-title":"Development of daptomycin susceptibility breakpoints for Enterococcus faecium and revision of the breakpoints for other enterococcal species by the Clinical and Laboratory Standards Institute","volume":"70","author":"Satlin","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.cmi.2020.04.027_bib38","doi-asserted-by":"crossref","first-page":"e00600","DOI":"10.1128\/JCM.00600-19","article-title":"The new, new daptomycin breakpoint for Enterococcus spp","volume":"57","author":"Humphries","year":"2019","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.cmi.2020.04.027_bib39","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1093\/jac\/dkx427","article-title":"MIC-based dose adjustment: facts and fables","volume":"73","author":"Mouton","year":"2018","journal-title":"J\u00a0Antimicrob Chemother"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X20302354?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X20302354?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:25:55Z","timestamp":1761117955000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X20302354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":39,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S1198743X20302354"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2020.04.027","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Daptomycin in the treatment of enterococcal bloodstream infections and endocarditis: a EUCAST position paper","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2020.04.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}